Trial · NCT04605159
Results by group148
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 148
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Infant Participants With Medically Assessed, RSV-associated Lower Respiratory Tract Illnesses (LRTIs) of Any Severity and RSV-associated Severe LRTIs From Birth to Day 181 Post-birth | RSV MAT Group - Infant | RSV-associated LRTIs of any severity | 16 | Participants | |
| Number of Infant Participants With Medically Assessed, RSV-associated Lower Respiratory Tract Illnesses (LRTIs) of Any Severity and RSV-associated Severe LRTIs From Birth to Day 181 Post-birth | Placebo Group - Infant | RSV-associated LRTIs of any severity | 24 | Participants | |
| Number of Infant Participants With Medically Assessed, RSV-associated Lower Respiratory Tract Illnesses (LRTIs) of Any Severity and RSV-associated Severe LRTIs From Birth to Day 181 Post-birth | RSV MAT Group - Infant | RSV-associated severe LRTIs | 8 | Participants | |
| Number of Infant Participants With Medically Assessed, RSV-associated Lower Respiratory Tract Illnesses (LRTIs) of Any Severity and RSV-associated Severe LRTIs From Birth to Day 181 Post-birth | Placebo Group - Infant | RSV-associated severe LRTIs | 14 | Participants | |
| Number of Infant Participants With at Least One Serious Adverse Event (SAE) From Birth to Day 181 Post-birth | RSV MAT Group - Infant | 640 | Participants | ||
| Number of Infant Participants With at Least One Serious Adverse Event (SAE) From Birth to Day 181 Post-birth | Placebo Group - Infant | 323 | Participants | ||
| Number of Infant Participants With at Least One Adverse Event (AE) Leading to Study Withdrawal From Birth to Day 181 Post-birth | RSV MAT Group - Infant | 19 | Participants | ||
| Number of Infant Participants With at Least One Adverse Event (AE) Leading to Study Withdrawal From Birth to Day 181 Post-birth | Placebo Group - Infant | 4 | Participants | ||
| Number of Infant Participants With at Least One Medically Attended AE (MAE) From Birth to Day 181 Post-birth | RSV MAT Group - Infant | 2321 | Participants | ||
| Number of Infant Participants With at Least One Medically Attended AE (MAE) From Birth to Day 181 Post-birth | Placebo Group - Infant | 1135 | Participants | ||
| Number of Infant Participants With at Least One SAE From Birth to Day 366 Post-birth | RSV MAT Group - Infant | 731 | Participants | ||
| Number of Infant Participants With at Least One SAE From Birth to Day 366 Post-birth | Placebo Group - Infant | 371 | Participants | ||
| Number of Infant Participants With at Least One AE Leading to Study Withdrawal From Birth to Day 366 Post-birth | RSV MAT Group - Infant | 21 | Participants | ||
| Number of Infant Participants With at Least One AE Leading to Study Withdrawal From Birth to Day 366 Post-birth | Placebo Group - Infant | 4 | Participants | ||
| Number of Infant Participants With at Least One MAE From Birth to Day 366 Post-birth | RSV MAT Group - Infant | 2706 | Participants | ||
| Number of Infant Participants With at Least One MAE From Birth to Day 366 Post-birth | Placebo Group - Infant | 1330 | Participants | ||
| Number of Infant Participants With RSV-associated Hospitalizations From Birth to Day 181 Post-birth | RSV MAT Group - Infant | 14 | Participants | ||
| Number of Infant Participants With RSV-associated Hospitalizations From Birth to Day 181 Post-birth | Placebo Group - Infant | 14 | Participants | ||
| Number of Infant Participants With All-cause LRTIs From Birth to Day 181 Post-birth | RSV MAT Group - Infant | 162 | Participants | ||
| Number of Infant Participants With All-cause LRTIs From Birth to Day 181 Post-birth | Placebo Group - Infant | 103 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04605159/results